Abstract
The aim of this first-in-man study is to assess effectiveness and safety of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C (Balton, Poland) in patients with stable coronary artery disease (CAD) and NSTE-ACS. BiOSS LIM C is a coronary dedicated bifurcation sirolimus-
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
